SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Spekulatius who started this subject10/29/2003 2:05:08 PM
From: WhatsUpWithThat  Read Replies (1) of 1840
 
re. ONCY (TSE:ONC). A significant step for ONCY IMIO (in my ignorant opinion). Always interested in informed other opinions.

Cheers
WUWT

ONCOLYTICS BIOTECH AND THE U.S. NATIONAL CANCER INSTITUTE TO COLLABORATE ON MULTIPLE CLINICAL TRIALS WITH REOLYSIN(R)
Support for multiple clinical trials to evaluate the efficacy of Reolysin in a range of cancers has been approved by the drug development group of the division of cancer treatment and diagnosis, United States National Cancer Institute (NCI).
The NCI approved Reolysin for collaborative development after an analysis of preclinical, GLP toxicology and clinical data. Oncolytics and the NCI will collaborate to select cancer indications and suitable development programs for a number of clinical trials. Oncolytics will provide Reolysin for all clinical trials conducted and sponsored by the NCI under a clinical trials agreement.
"We are pleased to collaborate with the National Cancer Institute to more broadly explore the potential of Reolysin," said Dr. Bradley Thompson, president and chief executive officer of Oncolytics. "This agreement will allow us to further evaluate the clinical utilization of Reolysin using different routes of administration and in combination with current standard therapies."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News